Luciana Robino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luciana Robino has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Gabriela Algorta
British Hospital , Montevideo, Montevideo , Uruguay
2 shared publications - Inés Bado
Departamento de Bacteriología y Virología, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo CP 11600, Uruguay
2 shared publications - Nicolas Cordeiro
Departamento de Bacteriología y Virología, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
2 shared publications Pablo Zunino
Departamento de Microbiología, Instituto de Investigaciones Biológicas Clemente Estable
2 shared publicationsPaola Scavone
Departamento de Microbiología, Instituto de Investigaciones Biológicas Clemente Estable
2 shared publications- Rafael Vignoli
Departamento de Bacteriología y Virología, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo CP 11600, Uruguay
2 shared publications
Latest Publications
- 13 April 2026
- Published by Springer Nature in Air Quality, Atmosphere & Health
- Vol. 19 (4) , 99
Assessment of indoor air quality, thermal comfort, and airborne microbiology in school buildings in Uruguay: a transdisciplinary approach
- 13 April 2026
- Published by Springer Nature in Air Quality, Atmosphere & Health
- Vol. 19 (4) , 99
Assessment of indoor air quality, thermal comfort, and airborne microbiology in school buildings in Uruguay: a transdisciplinary approach
- Open Access
- 15 May 2023
- Published by Archivos de Pediatria del Uruguay in Archivos de Pediatria Del Uruguay
- Vol. 94 (1) , e202
Características de la infección por SARS-CoV-2 en niños y adolescentes asistidos durante el primer año de la pandemia en un prestador privado de salud de Montevideo
Introducción: las infecciones respiratorias agudas virales suelen ser más frecuentes en niños que en adultos. Sin embargo, en el caso de la COVID-19 la mayoría de los casos pediátricos son leves o asintomáticos. Objetivo: describir las características clínicas y epidemiológicas de los niños con COVID-19 asistidos en un prestador de salud de Montevideo durante el primer año de la pandemia. Material y métodos: estudio descriptivo retrospectivo. Inclusión: pacientes menores de 15 años con reacción en cadena de la polimerasa en tiempo real (RT-PCR) positiva para SARS-CoV-2 entre el 13/3/2020 y el 31/03/2021. Principales variables: sintomatología, comorbilidades, nexo epidemiológico y generación de casos secundarios. Resultados: se realizaron 6.642 RT-PCR para SARS-CoV-2, 486 fueron positivas (7%). El 94% se diagnosticaron entre 12/2020 y 3/2021. Los síntomas respiratorios fueron los más frecuentes en el 98% de los casos sintomáticos. Un 60% presentaron fiebre. El 94% habían tenido contacto con un caso confirmado de COVID-19, 57% intradomiciliario, 31% en centro educativo, y 10% en actividades sociales. El 86% de los contactos eran adultos. Doscientos quince niños fueron el caso índice en el hogar y 73 (34%) generaron casos secundarios intradomiciliarios. Conclusiones: los resultados describen la situación clínica y epidemiológica de una población pediátrica de Montevideo durante el primer año de la pandemia. Dado los cambios constantes en la dinámica de transmisión y de casos es necesario continuar con la vigilancia y realización de este tipo de estudios para ajustar las definiciones de caso sospechoso y racionalizar la indicación de testeo.
- 15 May 2023
- Published by Archivos de Pediatria del Uruguay in Archivos de Pediatria Del Uruguay
- Vol. 94 (1) , e202
Open AccessCaracterísticas de la infección por SARS-CoV-2 en niños y adolescentes asistidos durante el primer año de la pandemia en un prestador privado de salud de Montevideo
Introducción: las infecciones respiratorias agudas virales suelen ser más frecuentes en niños que en adultos. Sin embargo, en el caso de la COVID-19 la mayoría de los casos pediátricos son leves o asintomáticos. Objetivo: describir las características clínicas y epidemiológicas de los niños con COVID-19 asistidos en un prestador de salud de Montevideo durante el primer año de la pandemia. Material y métodos: estudio descriptivo retrospectivo. Inclusión: pacientes menores de 15 años con reacción en cadena de la polimerasa en tiempo real (RT-PCR) positiva para SARS-CoV-2 entre el 13/3/2020 y el 31/03/2021. Principales variables: sintomatología, comorbilidades, nexo epidemiológico y generación de casos secundarios. Resultados: se realizaron 6.642 RT-PCR para SARS-CoV-2, 486 fueron positivas (7%). El 94% se diagnosticaron entre 12/2020 y 3/2021. Los síntomas respiratorios fueron los más frecuentes en el 98% de los casos sintomáticos. Un 60% presentaron fiebre. El 94% habían tenido contacto con un caso confirmado de COVID-19, 57% intradomiciliario, 31% en centro educativo, y 10% en actividades sociales. El 86% de los contactos eran adultos. Doscientos quince niños fueron el caso índice en el hogar y 73 (34%) generaron casos secundarios intradomiciliarios. Conclusiones: los resultados describen la situación clínica y epidemiológica de una población pediátrica de Montevideo durante el primer año de la pandemia. Dado los cambios constantes en la dinámica de transmisión y de casos es necesario continuar con la vigilancia y realización de este tipo de estudios para ajustar las definiciones de caso sospechoso y racionalizar la indicación de testeo.
- Open Access
- 1 April 2022
- Published by Elsevier in Revista Argentina de Microbiologia
- Vol. 54 (2) , 120-124
Antibiotic susceptibility and fosfomycin resistance characterization in a cohort of children older than 6 years of age with urinary tract infection
- 1 April 2022
- Published by Elsevier in Revista Argentina de Microbiologia
- Vol. 54 (2) , 120-124
Open AccessAntibiotic susceptibility and fosfomycin resistance characterization in a cohort of children older than 6 years of age with urinary tract infection
- Open Access
- 21 October 2020
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 10, 542755
Selection of Effective Antibiotics for Uropathogenic Escherichia coli Intracellular Bacteria Reduction
Urinary tract infections (UTI) are one of the most frequent bacterial infections in humans, being Uropathogenic Escherichia coli (UPEC), the most common etiological agent. The ability of UPEC to invade urothelial cells and to form intracellular bacterial communities (IBC) has been described. Therefore, UPEC can persist in the urinary tract producing recurrent infections, resisting antibiotic activity. The objective of the present work was to analyze the ability of a collection of UPEC clinical isolates to invade bladder epithelial cells in vitro and the activity of different classes of antibiotics on intracellular bacteria. We selected 23 UPEC clinical isolates that had been previously detected intracellularly in desquamated bladder epithelial cells from patients’ urine. A cellular invasion assay using the T24 bladder cell line was used. Intracellular bacteria was confirmed by laser confocal microscopy. All the strains were able to invade the cells with different percentages of intracellular bacterial survival (0.7 to 18%). However, no significant relationship was found between the percentage of in vitro infection and the presence of IBC in desquamated urine cells. In vitro, intracellular bacteria were confirmed in four representative strains by confocal laser microscopy. Ceftriaxone, ciprofloxacin and, azithromycin in vitro activity on intracellular bacteria were evaluated. Amikacin was used as a negative control. All the antibiotics tested, except amikacin, significantly decreased the number of intracellular bacteria. Ciprofloxacin was the antibiotic that induced the highest decrease percentage. Conclusions: All UPEC clinical isolates could invade bladder epithelial cells in vitro. Ceftriaxone, ciprofloxacin, and azithromycin can reduce the percentage of intracellular bacteria in vitro. In vivo studies are needed to confirm the utility of these antibiotics for intracellular bacteria reduction in UTI.
- 21 October 2020
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 10, 542755
Open AccessSelection of Effective Antibiotics for Uropathogenic Escherichia coli Intracellular Bacteria Reduction
Urinary tract infections (UTI) are one of the most frequent bacterial infections in humans, being Uropathogenic Escherichia coli (UPEC), the most common etiological agent. The ability of UPEC to invade urothelial cells and to form intracellular bacterial communities (IBC) has been described. Therefore, UPEC can persist in the urinary tract producing recurrent infections, resisting antibiotic activity. The objective of the present work was to analyze the ability of a collection of UPEC clinical isolates to invade bladder epithelial cells in vitro and the activity of different classes of antibiotics on intracellular bacteria. We selected 23 UPEC clinical isolates that had been previously detected intracellularly in desquamated bladder epithelial cells from patients’ urine. A cellular invasion assay using the T24 bladder cell line was used. Intracellular bacteria was confirmed by laser confocal microscopy. All the strains were able to invade the cells with different percentages of intracellular bacterial survival (0.7 to 18%). However, no significant relationship was found between the percentage of in vitro infection and the presence of IBC in desquamated urine cells. In vitro, intracellular bacteria were confirmed in four representative strains by confocal laser microscopy. Ceftriaxone, ciprofloxacin and, azithromycin in vitro activity on intracellular bacteria were evaluated. Amikacin was used as a negative control. All the antibiotics tested, except amikacin, significantly decreased the number of intracellular bacteria. Ciprofloxacin was the antibiotic that induced the highest decrease percentage. Conclusions: All UPEC clinical isolates could invade bladder epithelial cells in vitro. Ceftriaxone, ciprofloxacin, and azithromycin can reduce the percentage of intracellular bacteria in vitro. In vivo studies are needed to confirm the utility of these antibiotics for intracellular bacteria reduction in UTI.
- 1 April 2019
- Published by Oxford University Press (OUP) in Pathogens and Disease
- Vol. 77 (3)
Fosfomycin tromethamine activity on biofilm and intracellular bacterial communities produced by uropathogenic Escherichia coli isolated from patients with urinary tract infection
Fosfomycin tromethamine (FT), an old antibiotic revived as a new strategy to overcome antibiotic resistance, is an excellent option for the treatment of lower urinary tract infection (UTI). During UTI, Escherichia coli produces biofilms and could invade the bladder epithelial cells, developing intracellular bacterial communities (IBC). The present work aimed to evaluate the activity of FT on biofilms and IBC from clinical isolates of E. coli. A total of 38 E. coli clinical UTI isolates previously characterized as biofilm and IBC producers were studied. FT susceptibility was evaluated and its activity on 48 h biofilm was determined by microtiter plate-based biofilm assay comparing three different antibiotic concentrations. Two UPEC strains were selected to evaluate FT activity on IBC in vitro using T24 bladder cells. The survival percentage of intracellular bacteria after 24 h exposure to FT was calculated and compared to the percentage of intracellular bacteria without antibiotic. All the strains were susceptible to FT. FT produced a significant reduction of biofilms at the three concentrations tested, compared to the control. However, no statistically effect on IBC was observed after 24 h of fosfomycin exposure in cell culture. FT is a good option for bacterial biofilm reduction within UTI. However, it does not affect IBC.
- 1 April 2019
- Published by Oxford University Press (OUP) in Pathogens and Disease
- Vol. 77 (3)
Fosfomycin tromethamine activity on biofilm and intracellular bacterial communities produced by uropathogenic Escherichia coli isolated from patients with urinary tract infection
Fosfomycin tromethamine (FT), an old antibiotic revived as a new strategy to overcome antibiotic resistance, is an excellent option for the treatment of lower urinary tract infection (UTI). During UTI, Escherichia coli produces biofilms and could invade the bladder epithelial cells, developing intracellular bacterial communities (IBC). The present work aimed to evaluate the activity of FT on biofilms and IBC from clinical isolates of E. coli. A total of 38 E. coli clinical UTI isolates previously characterized as biofilm and IBC producers were studied. FT susceptibility was evaluated and its activity on 48 h biofilm was determined by microtiter plate-based biofilm assay comparing three different antibiotic concentrations. Two UPEC strains were selected to evaluate FT activity on IBC in vitro using T24 bladder cells. The survival percentage of intracellular bacteria after 24 h exposure to FT was calculated and compared to the percentage of intracellular bacteria without antibiotic. All the strains were susceptible to FT. FT produced a significant reduction of biofilms at the three concentrations tested, compared to the control. However, no statistically effect on IBC was observed after 24 h of fosfomycin exposure in cell culture. FT is a good option for bacterial biofilm reduction within UTI. However, it does not affect IBC.
- Open Access
- 1 August 2013
- Published by Sociedad Argentina de Pediatria in Archivos Argentinos de Pediatria
- Vol. 111 (4)
Colestasis neonatal por toxoplasmosis congénita. A propósito de un caso clínico
Neonatal cholestasis is the manifestation of many different diseases. Its early etiological diagnosis is crucial, since treatment before 60 days of life changes the prognosis in children with biliary atresia. Congenital toxoplasmosis can be asymptomatic in the newborn, or have mainly neurological, ophthalmological or gastrointestinal symptoms (hepatomegaly, cholestatic jaundice). Neonatal cholestasis secondary to congenital toxoplasmosis is not a situation frequently reported. We report the case of an infant with neonatal cholestasis due to a congenital toxoplasmosis, in order to discuss the difficulties in establishing the etiological diagnostic and to review the indications of invasive studies such as liver biopsy in these situations.
- 1 August 2013
- Published by Sociedad Argentina de Pediatria in Archivos Argentinos de Pediatria
- Vol. 111 (4)
Open AccessColestasis neonatal por toxoplasmosis congénita. A propósito de un caso clínico
Neonatal cholestasis is the manifestation of many different diseases. Its early etiological diagnosis is crucial, since treatment before 60 days of life changes the prognosis in children with biliary atresia. Congenital toxoplasmosis can be asymptomatic in the newborn, or have mainly neurological, ophthalmological or gastrointestinal symptoms (hepatomegaly, cholestatic jaundice). Neonatal cholestasis secondary to congenital toxoplasmosis is not a situation frequently reported. We report the case of an infant with neonatal cholestasis due to a congenital toxoplasmosis, in order to discuss the difficulties in establishing the etiological diagnostic and to review the indications of invasive studies such as liver biopsy in these situations.
- Open Access
- 16 April 2013
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 7 (04) , 361-364
Risk factors for the acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospitalized children
This item has no Follow the links below to access the full text.
- 16 April 2013
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 7 (04) , 361-364
Open AccessRisk factors for the acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospitalized children
This item has no Follow the links below to access the full text.